Mechanism of Action of Ocrelizumab in Multiple Sclerosis
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Immunology / Infectious Diseases, Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 11/19/2017 |
| Start Date: | October 12, 2017 |
| End Date: | December 31, 2019 |
| Contact: | anthony t reder, md |
| Email: | areder@neurology.bsd.uchicago.edu |
| Phone: | 7737026204 |
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and
stops MS inflammation.
stops MS inflammation.
The study will investigate immune cell subsets, and how the cells are modified by this
therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo,
and 12 mo.
Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated
measures.
therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo,
and 12 mo.
Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated
measures.
Inclusion Criteria:
- All patients who are eligible for Ocrelizumab therapy based on FDA criteria
Exclusion Criteria:
- All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
- Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that
would interfere with planned tests.
- Hepatitis B and HIV infections.
- Pregnant or lactating women.
- Hypersensitivity to trial medications.
We found this trial at
1
site
5801 South Ellis Avenue
Chicago, Illinois 60637
Chicago, Illinois 60637
773.702.1234
Phone: 773-702-8604
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
